Improvement in hepatic encephalopathy with rifaximin is associated with distinct changes in the metagenomic species in the saliva and stool microbiome and a reduction in systemic inflammation - results of the rifsys randomized controlled trial.

0 avis

Improvement in hepatic encephalopathy with rifaximin is associated with distinct changes in the metagenomic species in the saliva and stool microbiome and a reduction in systemic inflammation - results of the rifsys randomized controlled trial.

Archive ouverte

Edité par CCSD ; John Wiley & Sons -

International audience

Langue: en

Consulter en ligne

Consulter le document

Suggestions

Du même auteur

Rifaximin-α reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial

Archive ouverte | Patel, Vishal | CCSD

International audience. Background & Aims: Rifaximin-alpha is efficacious for the prevention of recurrent hepatic encephalopathy (HE), but its mechanism of action remains unclear. We postulated that rifaximin-alpha...

Global compositional and functional states of the human gut microbiome in health and disease

Archive ouverte | Lee, Sunjae | CCSD

International audience. The human gut microbiota is of increasing interest, with metagenomics a key tool for analyzing bacterial diversity and functionality in health and disease. Despite increasing efforts to expan...

Systematic analysis of gut microbiome reveals the role of bacterial folate and homocysteine metabolism in Parkinson’s disease

Archive ouverte | Rosario, Dorines | CCSD

International audience. Parkinson's disease (PD) is the most common progressive neurological disorder compromising motor functions. However, nonmotor symptoms, such as gastrointestinal (GI) dysfunction, precede thos...

Chargement des enrichissements...